Navigation Links
Injectable Psoriasis Drugs May Not Hike Heart Risks: Study
Date:8/23/2011

By Maureen Salamon
HealthDay Reporter

TUESDAY, Aug. 23 (HealthDay News) -- An extensive review of research investigating injectable drugs to treat psoriasis -- an autoimmune disorder triggering itchy, red skin patches -- indicates the medications are not linked to higher heart risks.

But, the study authors said a lack of complete information from drug makers impeded their ability to assess potential dangers noted in earlier research.

With the additional information, "it would have been a much more robust statistical analysis," said study author Dr. Caitriona Ryan, a dermatology resident at Baylor Research Institute in Dallas. "We could have adjusted for all the risk factors."

Researchers evaluated 22 randomized, controlled experiments involving more than 10,000 patients to determine if the rates of major adverse cardiovascular events -- including heart attack, stroke or cardiac death -- were affected by use of two types of so-called biologic psoriasis drugs. These drugs are injected systemically in some patients with moderate or advanced disease.

Some preliminary reports suggested an "excess" number of cardiovascular events linked to one drug type, IL-12/23 antibodies known by the brand names Stelara and Ozespa, and a small number of such events from the anti-tumor necrosis factor alpha (TNF-a) drugs Humira, Enbrel and Remicade. However, this study found no such link.

Ryan said the jury is ultimately still out on the cardiac safety of the biologic medications because drug manufacturers, who sponsored prior research, wouldn't release patient-level data associated with the medications, including patient demographics and prior known cardiac risk factors.

The short length of most randomized trials also discouraged an analysis of long-term side effects or other problems stemming from the drugs, she said.

The study is published in the Aug. 24/31 issue of the Journal of the American Medical Association.

As many as 7.5 million Americans have psoriasis, according to the National Psoriasis Foundation, with the most common form, plaque psoriasis, appearing as raised, red patches covered with silvery scales. Lesions can occur on any area of the body, and about 10 percent of sufferers also cope with a related form of arthritis.

Some research over the past decade has linked autoimmune diseases such as psoriasis with chronic systemic inflammation and a subsequent increase in cardiovascular risks, the scientists said.

During studies of Stelara and Ozespa, 10 of the 3,179 patients treated with those therapies had a major cardiovascular event, compared with none of the 1,474 patients treated with a placebo. In studies of Humira, Enbrel and Remicade, one of the 3,858 patients receiving those medications had a major cardiovascular event, compared to one of the 1,812 treated with a placebo.

"More than anything, the big conclusion of our study was this data was not powered to tell the risks," Ryan said.

Dr. Jerry Bagel, a spokesman for the National Psoriasis Foundation, said he doesn't prescribe Stelara as a first-line treatment for patients who have existing cardiovascular risk factors.

"It's just logic here . . . there may be some risk here, so let's not take risk where risk doesn't need to be amplified," said Bagel, also director of the Psoriasis Treatment Center of Central New Jersey and an associate clinical professor of dermatology at Columbia University in New York City.

More information

Learn more about psoriasis from the National Psoriasis Foundation.

SOURCES: Caitriona Ryan, M.B., dermatology resident, Baylor Research Institute, Dallas; Jerry Bagel, M.D., spokesman, National Psoriasis Foundation, and director, Psoriasis Treatment Center of Central New Jersey, East Windsor, and associate clinical professor, dermatology, Columbia University, New York City; Aug. 24/31 issue, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Injectable, Oral Birth Control Dont Threaten Glucose, Insulin Levels: Study
2. Project Runways Tim Gunn Returns to Address Psoriasis(TM) and Empower Patients to be Confident in Their Personal Style
3. Psoriasis is More Than Skin Deep
4. Psoriasis Tied to Raised Heart Risk
5. LeAnn Rimes Brings Battle With Psoriasis to Center Stage
6. Acne, Psoriasis Meds Dont Raise Fracture Risk
7. Insurance Woes Can Add to Burden of Psoriasis
8. Beer Linked to Psoriasis in Women
9. Kids With Psoriasis Often at Risk of Being Bullied: Survey
10. Psoriasis Linked to Raised Heart Risks
11. Psoriasis medication rises hope in the fight against multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Injectable Psoriasis Drugs May Not Hike Heart Risks: Study
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, but ... of auto glass for most makes and models, in Grand Prairie, TX, located in the ... They have been a family owned business for the past 40 years with 32 convenient ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
(Date:8/21/2017)... MO (PRWEB) , ... August 22, 2017 , ... PracticeMatch, ... fairs to help healthcare employers connect with physicians and advanced practitioners like nurse ... virtual career fairs in August through November of this year. The online career ...
(Date:8/21/2017)... ... 2017 , ... SportsEngine, Inc. , a division of ... of North Country Region Volleyball and will power registration, scheduling, and competition results ... sport management software to their member clubs. , SportsEngine provides financial ...
(Date:8/21/2017)... ... , ... PIXACORE , an independent full-service agency with a decade of ... the year by MM&M. , This is the first time PIXACORE has made the ... agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology: